0001213900-19-016442.txt : 20190821 0001213900-19-016442.hdr.sgml : 20190821 20190821160626 ACCESSION NUMBER: 0001213900-19-016442 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190821 DATE AS OF CHANGE: 20190821 EFFECTIVENESS DATE: 20190821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-347121 FILM NUMBER: 191043184 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 D 1 primary_doc.xml X0708 D LIVE 0001711786 Hoth Therapeutics, Inc. 1 ROCKEFELLER PLAZA, SUITE 1039 NEW YORK NY NEW YORK 10020 (646) 756-2997 NEVADA None None Corporation true 2017 Robb Knie 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Executive Officer Director David Briones 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Executive Officer Vadim Mats 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Kenneth Rice 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Anthony Hayes 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director David B. Sarnoff 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Pharmaceuticals Decline to Disclose 06b false 2019-08-16 false true true true false 10000 Laidlaw & Company (UK) Ltd. 119037 None None 521 FIFTH AVENUE, 12TH FLOOR NEW YORK NY NEW YORK 10175 CA CALIFORNIA FL FLORIDA GA GEORGIA IL ILLINOIS KY KENTUCKY LA LOUISIANA MA MASSACHUSETTS MI MICHIGAN NY NEW YORK NC NORTH CAROLINA OK OKLAHOMA PA PENNSYLVANIA TX TEXAS UT UTAH true 5000000 2037120 2962880 false 53 294455 0 Laidlaw will also receive warrants to purchase such number of shares of common stock equal to 10% of the number of shares of common stock sold in the offering, including shares of common stock issuable upon exercise of warrants sold in the offering. 0 false Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2019-08-21